Recombinant DNA Technology Market Size, Share, Opportunities, And Trends By Product (Medical, Non-medical), By Component (Expression System, Cloning Vector), By Application (Food & Agriculture, Health & Disease, Environment, Others), By End-Use (Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Others), And By Geography - Forecasts From 2023 To 2028

  • Published : Aug 2023
  • Report Code : KSI061616035
  • Pages : 150

The recombinant DNA technology market is estimated to grow at a CAGR of 7.71% during the forecast period.

Recombinant DNA (rDNA) refers to DNA that has been artificially created by combining genetic material from different sources, often from different organisms. This technology allows scientists to manipulate and modify genes to create new genetic sequences that don't naturally occur in nature. The huge burden of genetic disorders along with medical advancements is the major growth driver of the recombinant DNA technology market. Moreover, the expanding biopharmaceutical sector and growing investment in research studies are further expected to augment the market expansion.

Rising Prevalence of Genetic Disorders

Recombinant DNA technology plays a crucial role in gene therapy, which aims to treat genetic disorders by introducing functional genes into patients. The growing prevalence of genetic diseases is therefore expected to drive the recombinant DNA technology market. For instance, congenital diseases are the cause of around 240,000 newborn deaths globally within 28 days after birth every year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of congenital diseases as per the WHO report.

Medical Advancements and Therapeutics

Recombinant DNA technology has led to the development of a wide range of therapeutic products, including recombinant proteins, monoclonal antibodies, vaccines, and gene therapies. These products have revolutionized the treatment of various diseases, such as diabetes, cancer, and autoimmune disorders, driving demand in the healthcare industry. For example, CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) has revolutionized gene editing. CRISPR allows scientists to target specific DNA sequences and edit them with high precision. Additionally, vectors used to introduce recombinant DNA into host cells have become more efficient and versatile. Viral vectors, non-viral vectors, and CRISPR-associated systems are continually improved for precise gene delivery.

Expansion of the Biopharmaceutical Industry

The biopharmaceutical sector heavily relies on recombinant DNA technology for producing biologics. The industry's growth and increasing demand for personalized medicine have driven the expansion of the recombinant DNA technology market. For instance, in the year 2023, India's biotechnology sector surpassed an approximate value of $92 billion, indicating a growth of 15% compared to the preceding year as per the Indian National Investment and Facilitation Agency. Moreover, various collaborations are happening in the market aiding the growth. For instance, CytoReason and Pfizer signed an expanded partnership agreement in September 2022 to use artificial intelligence (AI) in drug development projects. For the following five years, the relationship is anticipated to continue.

Growing Investment in Research & Development

Researchers use recombinant DNA technology to create genetically modified organisms for studying gene function, drug discovery, and disease modeling. The increasing number of research studies and investments in the field is propelling the recombinant DNA technology market. For instance, in May 2022, PharmaJet announced that its collaborator, the Institute for Molecular Medicine (IMM), was granted $12 million by the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH). This funding is designated to facilitate clinical trials for beta-amyloid vaccines, utilizing both DNA and recombinant proteins, aimed at preventing Alzheimer's disease (AD).

Increasing Application in the Food and Agriculture Sector

Recombinant DNA technology has made significant contributions to the field of food and agriculture, offering innovative solutions to address various challenges and enhance productivity. Through recombinant DNA technology, crops can be engineered to have higher nutrient content, such as increased levels of vitamins, minerals, and essential amino acids. This addresses nutritional deficiencies in vulnerable populations. Additionally, during the July 2021 session, the 20th meeting of the Commission for Deepening Overall Reform under the China Central Committee discussed and endorsed the "Action Plan for the Revitalization of the Seed Industry." This plan sheds light on the vital role of biological breeding advancements, particularly in the research and development as well as the industrial implementation of genetically modified organisms (GMOs).

Restraints in the Market

The recombinant DNA technology market has experienced growth and development however some restraints or challenges can impact its expansion. For example, developing recombinant DNA-based products requires sophisticated technology, skilled personnel, and significant investment. The complexity of processes like gene editing and large-scale production can drive up costs. Additionally, the process of developing recombinant DNA-based products, from research to regulatory approvals, can be time-consuming. Rapid changes in technology or scientific understanding can affect the viability of ongoing projects.

North America is Expected to Grow Considerably

North America is expected to hold a significant share of the recombinant DNA technology market during the forecast period. The factors attributed to such a share are the higher prevalence of genetic disorders, medical advancements followed by earlier adoption, increasing healthcare expenditure, research studies, and government support. For instance, cystic fibrosis (CF) impacts approximately 35,000 individuals in the United States. Moreover, in December 2020, the FDA granted approval for a first-of-its-kind Intentional Genetic Alteration (the Ppl657 rDNA construct) for a breed of domestic pigs called GalSafe pigs. This clearance marks the first time an animal biotechnology product has ever been approved for use as food and/or a potential source for biomedical application.

Major Market Players

  • Elabscience® provides an extensive range of over 4000 proteins for research needs. This collection includes various types of proteins such as cytokines, growth factors, immune checkpoint proteins, CD antigens, FC receptors, enzymes, hormones, and more. It has a multi-expression system such as E.coli, yeast, mammalian cells, and insect cells and has a lower endotoxin.
  • Xpress Biologics is a firm that offers a wide array of services spanning from designing expression systems to pre-clinical production. The company has established a platform for the production of recombinant proteins and has successfully manufactured over 30 distinct proteins for therapeutic and imaging purposes.

Key Market Developments

  • In March 2022, VBI Vaccines Inc. launched PreHevbrio, a recombinant hepatitis B vaccine, in the United States. This vaccine is intended to prevent infections caused by all identified subtypes of the hepatitis B virus (HBV) in adults.
  • In August 2021, a genetically altered soybean seed called Conkesta E3 was released in Brazil by Corteva Inc. Conkesta E3 soybeans were recently given the green light by the European Union Commission, opening the door for the export of grains made from these beans to the European market for use as both food and feed.

Recombinant DNA Technology Market Scope:


Report Metric Details
Growth Rate CAGR of 7.71% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Billion
Segments Covered Product, Component, Application, End-Use, and Geography
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered MBL Life Science, Sino Biological Inc., Genentech, Prospec, Thermo Fisher Scientific, Biomay AG, ElabScience, Promega, Xpress Biologics
Customization Scope Free report customization with purchase



  • By Product
    • Medical
    • Non-medical
  • By Component
    • Expression System
    • Cloning Vector
  • By Application
    • Food & Agriculture
    • Health & Disease
    • Environment
    • Others
  • By End-Use
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Medical

5.3. Non-medical


6.1. Introduction

6.2. Expression System

6.3. Cloning Vector


7.1. Introduction

7.2. Food & Agriculture

7.3. Health & Disease

7.4. Environment

7.5. Others


8.1. Introduction

8.2. Biotechnology and Pharmaceutical Companies

8.3. Academic and Government Research Institutes

8.4. Others


9.1. Introduction

9.2. North America

9.2.1. United States

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. United Kingdom

9.4.2. Germany

9.4.3. France

9.4.4. Spain

9.4.5. Others

9.5. The Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Israel

9.5.4. Others

9.6. Asia Pacific

9.6.1. Japan

9.6.2. China

9.6.3. India

9.6.4. South Korea

9.6.5. Indonesia

9.6.6. Thailand

9.6.7. Others


10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix


11.1. MBL Life Science

11.2. Sino Biological Inc.

11.3. Genentech

11.4. Prospec

11.5. Thermo Fisher Scientific

11.6. Biomay AG

11.7. ElabScience

11.8. Promega

11.9. Xpress Biologics

MBL Life Science

Sino Biological Inc.



Thermo Fisher Scientific

Biomay AG



Xpress Biologics